SanoLiBio focuses on automation in circulating tumor cells (CTC) enrichment and analysis for diagnostic standardization. Cost-efficiency, accessibility, scalability, and diagnostic precision drive our innovation. We are perfecting our magnetic bead technology that is based on the negative selection principle for highest and untouched cell recovery and unbiased cell selection. So far, we achieved significant advancement in the field as credited by a peer-reviewed process (Schreier et al. 2017) with ongoing improvements.

SanoLiBio’s market priority is CTC enrichment, expanding rapidly into cancer therapy support and thrive to pioneer cancer screening for cancer prevention by CTC based liquid biopsy.